-$0.25 Earnings Per Share Expected for EQRx, Inc. (NASDAQ:EQRX) This Quarter

Wall Street brokerages expect EQRx, Inc. (NASDAQ:EQRX – Get Rating) to announce earnings of ($0.25) per share for the current quarter, according to Zacks. Zero analysts have made estimates for EQRx’s earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.19). The business is scheduled to issue its next earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that EQRx will report full-year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($0.83). For the next year, analysts expect that the business will post earnings of ($1.12) per share, with EPS estimates ranging from ($1.34) to ($0.89). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for EQRx.

EQRX has been the topic of a number of research reports. Jefferies Financial Group began coverage on EQRx in a research report on Friday, March 18th. They set a “buy” rating and a $5.60 target price on the stock. Cowen began coverage on EQRx in a research report on Friday, April 22nd. They issued an “outperform” rating for the company. Finally, Cowen began coverage on EQRx in a research note on Friday, April 22nd. They issued an “outperform” rating on the stock.

A number of large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new stake in shares of EQRx during the 1st quarter valued at about $226,000. Cannon Global Investment Management LLC raised its position in EQRx by 595.2% in the first quarter. Cannon Global Investment Management LLC now owns 173,800 shares of the company’s stock worth $718,000 after acquiring an additional 148,800 shares during the period. Sciencast Management LP purchased a new position in shares of EQRx during the 1st quarter worth $240,000. Corvex Management LP bought a new stake in shares of EQRx during the 4th quarter valued at $35,805,000. Finally, Exos Asset Management LLC purchased a new stake in shares of EQRx in the 4th quarter worth $59,000. 69.24% of the stock is owned by institutional investors and hedge funds.

Shares of EQRX opened at $3.72 on Friday. EQRx has a 52 week low of $2.63 and a 52 week high of $11.10. The firm has a fifty day moving average price of $4.13.

EQRx Company Profile (Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.

Featured Articles